Wire · operational-macro
FDA Approves Dostarlimab for Rectal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 October 2026 · Fusion42 review
The FDA has granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with stage II/III locally advanced rectal cancer that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR). This marks the first immunotherapy approval specifically for MSI-H or dMMR rectal cancer, potentially allowing eligible patients to avoid chemotherapy, radiation, and surgery.
This Wire brief sits within Fusion42's coverage of Health, and 9 sources have reported it.
◆ ◆ The Wire takeaway
You can now develop or position treatments around MSI-H/dMMR rectal cancers leveraging immunotherapy without the need for standard chemoradiation competition. GSK’s approval opens a clinical pathway where surgery might be avoidable, reshaping care models for this subset.
◆ Coverage
9 sources · 19 Oct 2026
◆ Topics